NASDAQ · MDAIW

Spectral AI, Inc.

$0.52 +$0.01 (+1.96%) 1D Market open

Key Metrics

$12.50M
Market cap
P/E · TTM
$16.93M
Revenue · TTM
−$13.88M
Net income
EPS · TTM $-0.58
Dividend yield
Free cash flow
Beta · 1Y 1.14
EBITDA · TTM −$13.85M
Gross margin 46.0%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its May 26 high, the share price fell 45%.

    Peak close $0.92 on May 26; trough close $0.51 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -45%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 15
    The stock moved +19.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 15
  • May 13
    The stock moved -20.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 13

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$5.30M
Shares outstanding
52-wk range$0.36 – $1.01
Avg volume · 20D35.2K
Net cash $7.20M
Book value / share$-0.37
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Spectral AI, Inc.
IPO dateSep 12, 2023
Employees65

Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.74
P/FCF
EV/EBITDA
EV/Sales0.31
Graham №

Profitability

Gross 46.0%
Operating -82.4%
Net -82.0%
FCF
ROE / ROIC 172.8% · 86.7%

Financial Health

Current ratio0.75
Quick ratio0.71
Debt / equity-0.51
Debt / EBITDA -0.33
Net cash $7.20M
Working capital−$5.29M

Cash Flow · TTM

Operating CF −$12.14M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-6.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings